Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
All News
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
The frequency of gout among patients with psoriatic disease was studied in two cohorts of 98,810 patients from the Health Professionals Follow-up Study (1986-2010) and the Nurses' Health Study (1998-2010).
A systematic review of treatments used in autoimmune chronic uveitis after failure of DMARDs and at least one TNF inhibitor identified few patients (12 children and 34 adults), and few trials examining rituximab (3), abatacept (3), tocilizumab (3), and 1 each with alemtuzumab and anakin
NEJM reports a 52 week, phase II trial in 293 adult patients with moderate-to-severe psoriasis (>10 BSA) who were randomized to receive either placebo, adalimumab or guselkumab - a novel IL-23 inhibitor.
On May 26, RheumNow.com reported that Amgen and Astra-Zenica suspended drug development for the IL-17 inhibitor brodalumab.
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
A 57 year old male is referred for arthritis of the hands for the last 8 years. He complains of pain, swelling, stiffness in the fingers only. He denies rash, bowel, urologic or ocular complaints. Over-the-counter NSAIDs have provided only partial relief.
In a 2 year follow-up of the DESIR cohort of patients with early inflammatory back pain (627 patients), TNF inhibitor use was associated with a significantly greater decrease in the median NSAID intake (from 54.9 to 1.9 in TNFi pts versus from 41.9 to 22.3 in non-TNFi pts, p0.05).
615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.
Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv
Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.
A retrospective review of 1285 US male veterans showed the prevalence of inflammatory eye disease to be 2%. Uveitis was most common (most being anterior uveitis), followed by keratitis, scleritis, episcleritis, and acute ischemic optic neuropathy.
The National Institute for Heath and Care Excellence has turned down Otezla for coverage under the U.K. healthcare system for psoriatic arthritis.
A randomized controlled trial of compared the outcomes of surgical decompression or physical therapy in 169 lumbar spinal stenosis patients. After two years, intention-to-treat analyses revealed no difference between groups.
Estimates on the prevalence of psoriatic arthritis among psoriasis patients has varied widely, ranging from 5-40%. A systematic review of the literature shows that prevalence of undiagnosed PsA was 15.5% when all studies were considered and 10.1% when only epidemiological studies were consi
A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.
Biologic Use Curtails Sepsis Events. An analysis of the German biologics register, RABBIT, examined the effect of current biologic therapy on future risk of sepsis (#OP0161).
Claims data analysis of 2115 ankylosing spondylitis patients without uveitis who started TNF inhibitor therapy revealed that the median time to the onset of uveitis was longest for those taking adalimumab (243 days), followed by etanercept (182 days) and infliximab (144 days). 
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
